Exploring the Potential Applications of STYK1 (NOK) as a Drug Target and Biomarker

Target Name: STYK1

NCBI ID: G55359

STYK1

Exploring the Potential Applications of STYK1 (NOK) as a Drug Target and Biomarker

STYK1 (Spermidine-Activated ProteinKinase 1) is a protein that plays a crucial role in cellular processes, including DNA replication, repair, and metabolism. As a result, STYK1 has been identified as a potential drug target and biomarker for various diseases. In this article, we will discuss the current understanding of STYK1, its potential applications as a drug target, and its role as a biomarker for various diseases.

Current Understanding of STYK1

STYK1 is a 26 kDa protein that is expressed in various cell types, including eukaryotes, bacteria, and archaea. It is composed of a 166 amino acid protein and a 14 kDa nucleotide-binding domain (NBD). The NBD is responsible for the protein's nuclear localization and functions as a binding site for various nucleotides, including DNA and RNA.

STYK1 has been shown to be involved in various cellular processes, including DNA replication, repair, and metabolism. It has been shown to be involved in the repair of DNA damage,

Protein Name: Serine/threonine/tyrosine Kinase 1

Functions: Probable tyrosine protein-kinase, which has strong transforming capabilities on a variety of cell lines. When overexpressed, it can also induce tumor cell invasion as well as metastasis in distant organs. May act by activating both MAP kinase and phosphatidylinositol 3'-kinases (PI3K) pathways (By similarity)

The "STYK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STYK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets